South Africa's Weight-Loss Squeeze: Regulators Crack Down, New Solutions Emerge

South Africa is currently grappling with a significant challenge in accessing popular weight-loss treatments, as regulators have intensified their crackdown on illegally compounded GLP-1 medicines, affecting an estimated 300,000 patients. In response to this void and the prohibitive cost of registered drugs, a new doctor-led service called Obiflex is stepping in, offering virtual consultations and 'buy-now-pay-later' payment options to make legitimate treatments more affordable and accessible. This move comes as the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) continue to enforce strict measures against pharmacies found manufacturing and distributing unregistered versions of drugs like semaglutide and tirzepatide. The regulatory push began in earnest around May and June 2026, with a joint investigation focusing on Pretoria-based iDexis pharmacy, which was accused of commercially distributing GLP-1 products under the guise of individual compounding, raising serious concerns about safety, quality, and the illegal importation of Active Pharmaceutical Ingredients (APIs). This led to product seizures, recalls, and stern warnings to healthcare professionals about potential disciplinary action for prescribing or dispensing these flagged medicines. Meanwhile, Novo Nordisk, the original developer of semaglutide (found in Ozempic and Wegovy), has been actively protecting its intellectual property, successfully securing an interim court order against iDexis and launching its own awareness campaigns about the risks of unregulated products. The landscape for GLP-1 medicines in South Africa is set for further transformation. With Novo Nordisk patent on semaglutide having recently expired in the country, the market is opening up to generic versions, promising to drive down costs further. SAHPRA is currently reviewing multiple applications for generics, with India's Sun Pharmaceutical Industries already receiving approval for one such version. Obiflex structured payment plans, alongside the anticipated influx of cheaper generic alternatives and Novo Nordisk own launch of a more affordable authorized copy, Extensior, aim to address the critical affordability gap, ensuring patients have safe, regulated, and financially manageable access to these highly sought-after weight management solutions.